SCHEMBL6829636

SCHEMBL6829636

C[C@H](Nc1nc(Cl)ncc1Br)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GALR3 O60755 1/20 0.44
NR2F2 P24468 1/20 0.44
IGF1R P08069 3/20 0.44
NTRK1 P04629 2/20 0.44
EGFR P00533 2/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HTT P42858 2/20 0.43
ALDH1A1 P00352 2/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
HDAC1 Q13547 4/20 0.42
HDAC6 Q9UBN7 4/20 0.42
HDAC3 O15379 3/20 0.42
HDAC2 Q92769 3/20 0.42
LDHA P00338 1/20 0.41
LDHB P07195 1/20 0.41
HDAC4 P56524 1/20 0.41
GAA P10253 1/20 0.41
SOS1 Q07889 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6210546 1.00 GALR3 (0.44) GALR3NR2F2IGF1RNTRK1EGFR
SCHEMBL6835083 1.00 GALR3 (0.44) GALR3NR2F2IGF1RNTRK1EGFR
SCHEMBL655672 0.86 EGFR (0.46) NTRK1EGFRMEN1KMT2ASOS1
SCHEMBL18488387 0.85 GALR3 (0.47) GALR3NR2F2MEN1KMT2AHTT
SCHEMBL20421869 0.85 GALR3 (0.47) GALR3NR2F2MEN1KMT2AHTT
SCHEMBL18489016 0.85 GALR3 (0.47) GALR3NR2F2MEN1KMT2AHTT
SCHEMBL22866341 0.84 HTT (0.48) GALR3NR2F2MEN1KMT2AHTT
SCHEMBL655605 0.82 KMT2A (0.47) GALR3NR2F2MEN1KMT2AHTT
SCHEMBL12067330 0.82 LDHB (0.46) GALR3NR2F2MEN1KMT2AHTT
SCHEMBL653243 0.82 KMT2A (0.47) GALR3NR2F2MEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220177-A1 Compound for the treatment of abnormal cell growth CCNA1, CCNB1, CCNT1 GALR3 1776/4885NR2F2 1222/4885IGF1R 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.